Katoh N, Hirano S, Yasuno H
Department of Dermatology, Kyoto Prefectural University of Medicine, Japan.
J Dermatol. 1996 May;23(5):335-9. doi: 10.1111/j.1346-8138.1996.tb04026.x.
Two infants with solitary mastocytoma were treated with 5 mg/kg/day of tranilast [N-(3',4'-dimethoxycinnamoyl)anthranilic acid], a mast cell stabilizing compound extracted from Nandina domestica. Tranilast was administered orally in three divided doses. In one infant, a topical corticosteroid was also applied in combination with the oral tranilast. Patients experienced symptomatic relief, and nodules resolved almost completely after eight weeks of treatment. Tranilast therapy was continued for six months. No relapses were observed after discontinuation of therapy. We speculated that tranilast not only inhibited mast cell degranulation but also reduced the number of mast cells.
两名患有孤立性肥大细胞瘤的婴儿接受了曲尼司特[N-(3',4'-二甲氧基肉桂酰基)邻氨基苯甲酸]治疗，剂量为5毫克/千克/天，曲尼司特是从南天竹中提取的一种肥大细胞稳定剂。曲尼司特分三次口服给药。在一名婴儿中，还联合使用了局部皮质类固醇与口服曲尼司特。患者症状缓解，治疗八周后结节几乎完全消退。曲尼司特治疗持续了六个月。停药后未观察到复发。我们推测曲尼司特不仅抑制肥大细胞脱颗粒，还减少了肥大细胞的数量。
